Moderna has announced that the FDA will initiate the review of its seasonal influenza vaccine candidate, mRNA-1010.
Novo Nordisk and United Laboratories’ jointly developed triple G drug has achieved a 19.7% weight loss in a Phase II trial in ...
Patients with HIV showed lower cases of steatotic liver disease when switched to ViiV Healthcare’s Dovato compared to ...
C4 Therapeutics has dosed the first patient in its Phase II MOMENTUM trial of cemsidomide, an oral IKZF1/3 degrader, combined with dexamethasone for patients with RRMM.
In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema ...
The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway” ...
Gossamer Bio has reported topline data from the Phase III PROSERA study evaluating seralutinib in patients with PAH.
Teva Pharmaceuticals and Sanofi’s monoclonal antibody (mAb) has shown durable clinical and endoscopic efficacy in a Phase IIb ...
Compass will now seek approval for COMP360 in TRD, which could become the first classic psychedelic to gain the FDA’s ...
The North Midlands CRDC has recruited its first patient, representing the UK’s initial participation in a clinical trial of ...
Prasad and Makary disagree that some may believe this move to just one pivotal trial shows the FDA relaxing its standards.
Another of Pfizer’s Braftovi regimens has shown benefit in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results